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Biotechnology Derived Medicines, Pan American Health Organization, 525 23rd Street N.W., Ofﬁce 431E, Washington, DC 20037, USAIn order to be better informed regarding regulations in place in
the Region for biological and biotechnological products, a review of
the regulation of biological and biotechnological products in Latin
American and Caribbean countries was conducted by the Pan
American Health Organization (PAHO) and published in Biologicals
in 2009 [1]. Results indicated that most of the countries surveyed in
2008 had regulations in place for biological products. Some coun-
tries had licensed therapeutic biological medicines as “biosimilars”
but information about the pathways used to grant a license under
this category was not surveyed.
Countries in the Americas have shown a great interest in having
harmonized documents for licensing biotechnological products.
Efforts to harmonize regulations among Member States include the
work of the Pan American Network on Drug Regulatory Harmoniza-
tion (PANDRH). PANDRH is formed by all Member States of the
Americas. This network is an initiative of all the National Regulatory
Authorities (NRA’s) in the Region and PAHO. It currently supports the
processes of pharmaceutical regulatory harmonization in the Amer-
icaswithin the frameworkof national and sub-regionalhealthpolicies
and recognizing pre-existing asymmetries. The main components of
PANDRH are: the Pan American Conference, the Steering Committee,
Technical working groups in priority areas and the PAHO [2].
In January 2010, the Steering Committee of PANDRH approved
the establishment of a technical working group on biotechnological
products (BIO WG). The mission of the BIO WG is to promote the
development of the regulation of biotechnological products in the
countries of the Americas region, and to generate more effective
and harmonized mechanisms for the regulation of this category of
medicines. The members of this group are the NRA’s of Argentina,
Barbados, Brazil, Canada, Chile, Cuba, Guatemala, Panama, Peru,
Trinidad & Tobago and Venezuela, pharmaceutical industries rep-
resented by FIFARMA and ALIFAR, and PAHO which acts as Secre-
tariat. The country coordinator of this group is Brazil.
The main objectives of the BIO WG are to:
1. Compile a list of all regulations related to biotechnological
products in place at country level and make them available at
the regional level, including those for similar biological prod-
ucts where available.* Tel.: þ1 202 974 3353.
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doi:10.1016/j.biologicals.2011.06.0102. Establish a glossary of terms to help understand the situation in
Member States and to facilitate further development of related
documents.
3. Promote the exchange of information among National Regu-
latory Authorities of the Region.
4. Identify regional documents and guidelines for development in
theshort andmediumtermandelaborateon themasappropriate.
5. Identify other issues related to the regulation of biotechno-
logical products that may require special treatment and
establish working plans to address them.
6. Develop tools and training programs to strengthen capacity
building among the National Regulatory Authorities of
Members States in relation to the regulatory oversight of
biotechnological products and related matters.
World Health Organization guidance and general developed
documents on biological products are well known and currently
used by countries in the PAHO Region for the establishment of local
regulations. Therefore, translation into Spanish and Portuguese of
the WHO Guidelines on evaluation of similar biotherapeutic prod-
ucts (SBPs) [3] and acquiring copyright permission for its later
publication was part of the working plan of the BIO WG, and it is
already available [4].
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